Eisai Co., Ltd.

Industry

  • Distributors
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Biotechnology

Other Names/Subsidiaries

  • AkaRx
  • EA Pharma
  • EIDIA
  • Eisai (Thailand) Marketing
  • Eisai China Holdings
  • Eisai Laboratorios
  • Eisai Mexico
  • Eisai Participacoes (Brazil Subsidiary)
  • Eisai Vietnam
  • H3 Biomedicine
  • HI-Eisai Pharmaceutical
  • Jingyi Weixiang (Shanghai) Health Industry Development
  • KAN Research Institute
  • Laboratoires Biodim
  • Liaoning TianYi Biological Pharmaceutical
  • MGI Pharma
  • Morphotek
  • Sannova (formerly Sansho Pharmaceutical)
  • TransMolecular
  • Tsukuba Research Laboratories
  • Zycos
See more in Biomedtracker

Latest on Eisai Co., Ltd.

Scrip

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

Alzheimer’s disease (AD) drug development during the last several years showed that amyloid-clearing medicines worked best in patients treated early in their disease progression, and the first two ant

Scrip

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai reported its fiscal year 2024 earnings on 15 May for the 12 months ended 31 March, which included fiscal year 2025 guidance for its most scrutinized product, the anti-amyloid antibody Leqembi (l

Scrip

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen protected itself from tariffs on products imported from outside the US before there ever was a notion that US President Donald Trump would enact double-digit tariffs this year by virtue of wher

Pink Sheet

Leqembi Launch Set For Germany & Austria After Winning EU Approval At Last

 
• By Neena Brizmohun

Eisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear